Conclusion
Mitral regurgitation is a complex disorder involving a multitude of components of the mitral apparatus. TMVT directed at these components, as described, are available at varying stages of development and able to treat different pathophysiological substrates. Advancements in therapies and the possbility of combining technologies may further improve their efficacy and safety. TMVR may emerge as an alternative or even a more suitable approach, while preserving the mitral apparatus. Early data on transcatheter mitral ViV and ViR implantation are encouraging, and may be an alternative to reoperation in the high-risk patient. Overall, percutaneous mitral therapies are evolving and options to treat patients with this complicated disorder are expanding.